Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + FOLFOX + TACE
- Development stage
- Unknown
- Lead developer
- BinYong Liang
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intra-arterial
01
Overview
This combination regimen is a multi-modal neoadjuvant therapy being evaluated for the treatment of resectable hepatocellular carcinoma (HCC) with high-risk recurrence factors. It consists of the PD-1 inhibitor sintilimab, the VEGF-targeting monoclonal antibody bevacizumab, the FOLFOX chemotherapy regimen (oxaliplatin, leucovorin, and 5-fluorouracil) administered via hepatic arterial infusion chemotherapy (HAIC), and conventional transarterial chemoembolization (cTACE). The regimen is designed to downstage tumors and reduce the risk of post-surgical recurrence by combining systemic immunotherapy and targeted therapy with localized chemoembolization and infusion chemotherapy. The localized components (HAIC and TACE) aim to induce tumor necrosis and release tumor-associated antigens, potentially enhancing the systemic immune response triggered by sintilimab.
- Other names
- Sintilimab + Bevacizumab + FOLFOX-HAIC + TACESequential FOLFOX-HAIC Followed by TACE Combined With Sintilimab Plus Bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNAVEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sintilimab + bevacizumab + FOLFOX + TACE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + FOLFOX + TACE.